Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/43836
Title: Biologics for paediatric severe asthma: trick or TREAT?
Authors: Saglani, S
Bush, A
Carroll, W
Cunningham, S
Fleming, L
Gaillard, E
Gupta, A
Murray, C
Nagakumar, P
Paton, J
Roberts, G
Seddon, P
Sinha, I
First Published: 26-Feb-2019
Publisher: Elsevier
Citation: Lancet Respiratory Medicine, 2019, 7(4), pp. 294-296.
Abstract: While most asthma in UK children can be controlled with low-moderate dose inhaled corticosteroids (ICS), there remains a small group with severe disease and poor control despite maximal treatment whose needs are unmet because of discrimination compared to adults. Severe asthma is a commissioned service for adults with only named specialist centres able to assess patients and prescribe biologics. A systematic assessment at a dedicated severe asthma centre is associated with improved quality of life and asthma control and a reduction in health-care utilisation(1). This multidisciplinary assessment helps to identify remediable factors such as poor adherence and ensures that appropriate patients are started on costly biologics. In contrast, although international guidelines exist(2), there is no such service provision or specification for children, despite clear evidence of their long-term morbidity, including development of chronic obstructive pulmonary disease in adulthood(3), and the potential risks associated with the prescription of biologics.
DOI Link: 10.1016/S2213-2600(19)30045-1
eISSN: 2213-2619
Links: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213260019300451?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213260019300451%3Fshowall%3Dtrue&referrer=
http://hdl.handle.net/2381/43836
Embargo on file until: 1-Oct-2019
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © Elsevier 2019. After an embargo period this version of the paper will be an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Description: The file associated with this record is under embargo until 6 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
paediatric severe asthma-LRM comment-101218-final.pdfPost-review (final submitted author manuscript)175.16 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.